patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
favipiravir - versus potential COVID-19 treatments - for COVID-19 mild to moderate
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.69 [0.28, 1.68]< 1 0% 1 study (1/-) 79.1 % NA not evaluable crucial - deaths 1.13 [0.75, 1.70]< 1 0% 6 studies (6/-) 27.3 % some concern not evaluable moderate crucial - clinical improvement 1.66 [1.28, 2.15]> 1 0% 4 studies (4/-) 100.0 % some concern not evaluable moderate important - clinical improvement (14-day) 1.10 [0.58, 2.11]> 1 31% 2 studies (2/-) 61.5 % some concern not evaluable moderate important - clinical improvement (28-day) 1.32 [0.86, 2.03]> 1 70% 2 studies (2/-) 89.4 % some concern not evaluable moderate important - clinical improvement (7-day) 1.62 [1.15, 2.28]> 1 0% 2 studies (2/-) 99.7 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.16 [0.92, 1.46]> 1 66% 6 studies (6/-) 90.0 % some concern serious moderate important - hospital discharge 1.08 [0.85, 1.35]> 1 45% 3 studies (3/-) 73.2 % some concern not evaluable moderate important - hospitalization 0.12 [0.01, 2.26]< 1 0% 1 study (1/-) 92.0 % NA not evaluable important - mechanical ventilation 0.41 [0.02, 9.32]< 1 83% 2 studies (2/-) 70.8 % some concern not evaluable moderate important - mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 1 0% 1 study (1/-) 98.2 % NA not evaluable important - viral clearance 1.54 [0.97, 2.42]> 1 72% 6 studies (6/-) 96.8 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.13 [0.82, 1.57]> 1 54% 3 studies (3/-) 77.1 % low not evaluable high important - viral clearance by day 14 1.30 [0.50, 3.36]> 1 48% 2 studies (2/-) 70.5 % some concern not evaluable moderate important - viral clearance by day 7 1.44 [0.78, 2.65]> 1 61% 3 studies (3/-) 87.5 % some concern not evaluable moderate important - ICU admission 1.32 [0.88, 1.99]< 1 0% 2 studies (2/-) 9.1 % some concern not evaluable moderate non important - 00 serious adverse events 2.73 [0.55, 13.60]< 1 0% 4 studies (4/-) 11.1 % some concern not evaluable moderate important - adverse events 3.33 [1.23, 9.02]< 1 87% 5 studies (5/-) 0.9 % some concern serious moderate non important -
LoD: level of statistical demonstration:
